文献速递浆细胞疾病

三种人骨髓瘤细胞系小鼠异种移植模型的建立与比较

[Establishment and comparison of three human multiple myeloma cell line transplantation models in mice].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2022-01-01

研究将人骨髓瘤细胞系ARP1、MM.1S和NCI-H929经皮下或尾静脉植入NOD/SCID小鼠,比较三种细胞的成瘤、肿瘤负荷与生物学特点。三种细胞皮下接种约2周均成瘤;ARP1尾静脉移植后外周血可检出κ轻链,6周时骨髓检出人CD138(+)CD38(+)细胞,硼替佐米可显著降低肿瘤负荷。

要点

  • ARP1、MM.1S和NCI-H929细胞皮下接种NOD/SCID小鼠约2周均形成局部肿瘤。
  • ARP1尾静脉移植第20天外周血κ轻链为8.2±1.0 ng/ml。
  • 尾静脉移植6周ARP1组骨髓检出人CD138(+)CD38(+)细胞,MM.1S和NCI-H929组未检出。

核心结论

  • ARP1、MM.1S和NCI-H929细胞系构建的小鼠模型可作为MM发病机制及临床研究的良好模型。

研究设计与样本

  • 将人骨髓瘤细胞系ARP1、MM.1S和NCI-H929分别经皮下或尾静脉植入经(137)Cs照射后的NOD/SCID小鼠。
  • 每周观察小鼠生存情况并监测肿瘤负荷。

主要发现

  • 皮下移植ARP1、MM.1S和NCI-H929细胞的小鼠在两周内均可形成局部肿瘤,免疫荧光检测支持浆细胞肿瘤。
  • 尾静脉移植后第20天ARP1组小鼠外周血中检出κ轻链(8.2±1.0)ng/ml。
  • 尾静脉移植6周左右ARP1组小鼠出现体重下降、精神萎靡、下肢逐渐瘫痪,骨髓中检测到人CD138(+)CD38(+)细胞群。
  • 硼替佐米治疗显著降低肿瘤负荷[(5.7±0.2)%对(21.3±2.1)%,P<0.01]。
  • MM.1S和NCI-H929组小鼠骨髓中未检测到人CD138(+)CD38(+)细胞群。

关键数值与推荐

  • 尾静脉移植后第20天ARP1组小鼠外周血κ轻链为(8.2±1.0)ng/ml。
  • 硼替佐米治疗后肿瘤负荷为(5.7±0.2)%对(21.3±2.1)%,P<0.01。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To establish three types of xenotransplantation models using human myeloma cell lines ARP1, MM.1S, and NCI-H929 and to compare the proliferation, tumor load, and biological characteristics of the three types of cells after transplantation. Methods: Suspensions of human myeloma cell lines ARP1, MM.1S, and NCI-H929 were implanted into NOD/SCID mice by subcutaneous injection or tail vein injection. The survival of the mice was observed weekly, and the tumor load was measured. Flow cytometry was used to detect the proportion of CD138(+) cells in tumor tissue or the mouse bone marrow. CD138(+) cells and light chains were detected by immunofluorescence. Light chains in bone marow and peipheral blood were measured by ELISA, and bone disease was assessed by micro-CT. Results: Mice injected with ARP1, MM.1S, and NCI-H929 cells all formed tumors subcutaneously in about 2 weeks. Immunofluorescence detection supported plasma cell tumors. Kappa light chains were detected in the peripheral blood of ARP1 mice on day 20 after tail vein transplantation (8.2±1.0 ng/ml) . After 6 weeks of tail vein transplantation, mice in the ARP1 group showed signs of weight loss, mental depression, and dragging legs, and human CD138(+)CD38(+) cells were detected in the bone marrow (BM) . Furthermore, bortezomib (BTZ) treatment given once the tumor was established significantly reduced the tumor burden[ (5.7±0.2) % vs (21.3±2.1) %, P<0.01]. Human CD138(+)CD38(+) cells were not detected in the BM of the MM.1S or NCI-H929 groups. Conclusion: The results of this study suggest that the mouse models constructed by the three cell lines (ARP1, MM.1S, and NCI-H929) can be used as models for the pathogenesis and clinical research of MM. 目的: 利用人骨髓瘤细胞系ARP1、MM.1S和NCI-H929建立异种移植模型,并对三种细胞移植后生长周期、肿瘤负荷和生物学特点进行比较。 方法: 将ARP1、MM.1S和NCI-H929细胞分别由皮下或尾静脉植入经(137)Cs照射后的NOD/SCID小鼠,每周观察小鼠的生存情况,监测肿瘤负荷。应用流式细胞术检测小鼠肿瘤组织或骨髓中CD138(+)细胞的比例。采用免疫荧光检测肿瘤组织细胞的CD138和免疫球蛋白轻链表达。ELISA法检测骨髓和外周血中的免疫球蛋白轻链,micro-CT评价骨病变。 结果: 皮下移植ARP1、MM.1S和NCI-H929细胞的小鼠在两周内均可形成局部肿瘤,免疫荧光检测支持浆细胞肿瘤。尾静脉移植后第20天时可在ARP1组小鼠外周血中检测出κ轻链[(8.2±1.0)ng/ml]。尾静脉移植6周左右,ARP1组小鼠出现体重下降、精神萎靡、下肢逐渐瘫痪等表现,骨髓中能检测到人CD138(+)CD38(+)细胞群,予硼替佐米治疗可显著降低肿瘤负荷[(5.7±0.2)%对(21.3±2.1)%,P<0.01]。MM.1S和NCI-H929组小鼠骨髓中未检测到人CD138(+)CD38(+)细胞群。 结论: ARP1、MM.1S和NCI-H929细胞系构建的小鼠模型可作为MM发病机制及临床研究的良好模型。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Liu LT, Wei XJ, Gong LX, et al. [Establishment and comparison of three human multiple myeloma cell line transplantation models in mice]. Zhonghua Xue Ye Xue Za Zhi. 2022. PMID: 35680600. doi:10.3760/cma.j.issn.0253-2727.2022.05.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。